Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors.
Haematologica
; 109(1): 343-350, 2024 Jan 01.
Article
in En
| MEDLINE
| ID: mdl-37470152
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Lymphoma, Mantle-Cell
Type of study:
Prognostic_studies
Limits:
Adult
/
Humans
Language:
En
Journal:
Haematologica
Year:
2024
Document type:
Article
Country of publication:
Italy